Akero Therapeutics to Speak at BofA Securities 2024 Health Care Conference

28 June 2024

SOUTH SAN FRANCISCO, Calif., May 08, 2024 – Akero Therapeutics, Inc. (Nasdaq: AKRO), a company focused on developing innovative treatments for serious metabolic diseases, has announced its participation in the BofA Securities 2024 Health Care Conference. The event will take place on Tuesday, May 14, 2024, at 5:00 p.m. P.T. in Las Vegas, NV. Interested parties can access a live webcast of the presentation through the investor relations section of Akero's website at www.akerotx.com. An archived replay will also be available post-presentation.

Akero Therapeutics specializes in creating transformational therapies for patients with severe metabolic conditions that have significant unmet medical needs, including Metabolic Associated Steatohepatitis (MASH). The company’s principal product candidate, EFX, is currently being tested in the SYMMETRY study, a 96-week Phase 2b clinical trial targeting patients with compensated cirrhosis due to MASH (F4 fibrosis). Additionally, EFX is under evaluation in two Phase 3 clinical trials: the SYNCHRONY Histology study, which involves patients with pre-cirrhotic MASH (F2-F3 fibrosis), and the SYNCHRONY Real-World study, focusing on patients with MASH (F1-F3 fibrosis) or Metabolic Associated Steatotic Liver Disease (MASLD). Another study, the SYNCHRONY Outcomes trial for patients with compensated cirrhosis due to MASH (F4 fibrosis), is slated to begin in the second quarter of 2024.

The Phase 3 SYNCHRONY program is based on the successful results of two earlier Phase 2b clinical trials: the HARMONY study, which involved patients with pre-cirrhotic MASH (F2-F3), and the SYMMETRY study, which included patients with compensated cirrhosis due to MASH (F4). Akero Therapeutics is headquartered in South San Francisco and continues to drive forward its mission of addressing critical gaps in treatment for metabolic diseases. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!